IV
IVA.US Inventiva Sa
- Market cap
- USD 880M
- P/E
- -
- P/B
- 13.44x
- ROE
- -838.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is IVA.US undervalued?
Graham numberThe Graham number of Inventiva Sa cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Inventiva Sa fundamental analysis
No fundamental analysis for Inventiva Sa yet.
Inventiva Sa stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Inventiva Sa
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharido…
Full company profileInventiva Sa financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Inventiva Sa annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 9.45M | 6.52M | 3.20M | 7.00M | 372K | 4.19M | 12.2M | 17.5M | 9.20M | 4.48M | 2.67M |
| Gross Profit | 7.96M | 5.28M | 2.23M | 7.00M | 372K | 4.19M | 12.2M | 17.5M | 9.20M | 1.51M | -645K |
| Operating Income | -13.0M | -20.9M | -33.3M | -30.3M | -29.7M | -52.1M | -57.1M | -103M | -97.6M | -131M | -289M |
| EBITDA | -10.4M | -21.5M | -32.0M | -28.6M | -27.8M | -52.7M | -55.4M | -102M | -167M | -128M | -297M |
| Net Income | -7.05M | -17.2M | -33.6M | -30.2M | -31.6M | -49.6M | -54.3M | -110M | -184M | -340M | -495M |
| EPS | -0.45 | -1.11 | -1.64 | -1.28 | -0.93 | -1.27 | -1.31 | -2.43 | -3.54 | -1.82 | -1.81 |
| Balance Sheet | |||||||||||
| Total Assets | 48.9M | 74.4M | 79.8M | 57.0M | 139M | 122M | 116M | 69.6M | 119M | 249M | 251M |
| Total Liabilities | 13.1M | 10.4M | 18.2M | 15.6M | 27.7M | 33.1M | 70.5M | 102M | 226M | 278M | 192M |
| Shareholders' Equity | 35.7M | 64.0M | 61.6M | 41.4M | 111M | 88.9M | 45.5M | -32.0M | -107M | -29.0M | 59.0M |
| Cash & Short-term Investments | 24.9M | 59.1M | 56.7M | 35.8M | 113M | 86.6M | 87.8M | 27.3M | 96.6M | 99.3M | 166M |
| Total Debt | 628K | 482K | 2.20M | 114K | 10.1M | 10.1M | 34.5M | 37.5M | 54.3M | 59.4M | 66.6M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -14.9M | -17.0M | -34.2M | -28.4M | -30.6M | -47.6M | -44.9M | -81.6M | -85.9M | -101M | -226M |
| Capital Expenditure | 228K | 428K | 549K | 136K | 292K | 534K | 561K | 540K | 333K | 237K | 725K |
| Free Cash Flow | -15.1M | -17.4M | -34.8M | -28.5M | -30.9M | -48.2M | -45.5M | -82.2M | -86.3M | -101M | -227M |
| Ratios | |||||||||||
| ROE | -19.7% | -26.9% | -54.6% | -73.0% | -28.4% | -55.9% | -119.3% | - | - | - | -838.8% |
| ROA | -14.4% | -23.2% | -42.1% | -53.1% | -22.8% | -40.7% | -46.8% | -158.7% | -154.8% | -136.7% | -197.0% |
| Net Profit Margin | -74.6% | -264.2% | -1,051.5% | -431.9% | -8,500.8% | -1,183.5% | -445.6% | -631.8% | -2,002.7% | -7,587.8% | -18,544.1% |
| Debt to Equity | 0.02x | 0.01x | 0.04x | 0.00x | 0.09x | 0.11x | 0.76x | - | - | - | 1.13x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Inventiva Sa dividends
Inventiva Sa has not paid dividends in the last 9 fiscal years.
Who owns Inventiva Sa
- Insiders 0.77%
- Institutions 39.94%
- Public & others 59.29%
- Shares outstanding 239M
- Free float 180M
Top funds holding IVA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Franklin Biotechnology Discv A(acc)USD | 2.97M | 1.24% | +54.11% | Sep 2026 |
| Franklin Biotechnology Discovery A | 1.62M | 0.68% | +54.99% | Sep 2026 |
| abrdn Life Sciences Investors | 1.60M | 0.67% | 0.00% | Oct 2026 |
| abrdn World Healthcare | 1.55M | 0.65% | +12.29% | Sep 2026 |
| Fidelity Advisor Biotechnology I | 685K | 0.29% | 0.00% | Sep 2026 |
| International Biotechnology Ord | 592K | 0.25% | 0.00% | Jul 2026 |
| Fidelity Series Small Cap Core | 526K | 0.22% | +286.23% | Aug 2026 |
| Strategic Advisers Fidelity US TtlStk | 336K | 0.14% | +52.22% | Sep 2026 |
| Simplify Propel Opportunities ETF | 313K | 0.13% | 0.00% | Oct 2026 |
| Fidelity Small Cap Stock | 154K | 0.06% | 0.00% | Aug 2026 |
| IA Clarington Global Health Care I | 82.9K | 0.03% | 0.00% | Sep 2026 |
| Harbor Health Care ETF | 34.7K | 0.01% | 0.00% | Oct 2026 |
| China Universal Gbl YLBJ QDII CNH | 21.6K | 0.01% | 0.00% | Jun 2026 |
| ActivePassive International Equity ETF | 13.8K | 0.01% | 0.00% | Oct 2026 |
| Harbor Health Care UCITS ETF Acc | 11.7K | 0.00% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 2.46K | 0.00% | -93.75% | Aug 2026 |
| Fidelity Small Cap Stock K6 | 2.40K | 0.00% | 0.00% | Aug 2026 |
Top institutions holding IVA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Caligan Partners LP | 8.16M | 3.41% | +64.09% | Jun 2026 |
| Samsara BioCapital, LLC | 6.31M | 2.64% | +21.56% | Jun 2026 |
| Nantahala Capital Management, LLC | 5.37M | 2.25% | 0.00% | Jun 2026 |
| Paradigm Biocapital Advisors LP | 4.00M | 1.67% | 0.00% | Jun 2026 |
| Andera Partners | 3.63M | 1.52% | +99.83% | Jun 2026 |
| ADAR1 Capital Management LLC | 3.61M | 1.51% | +65.87% | Jun 2026 |
| Millennium Management LLC | 3.51M | 1.47% | +17.56% | Jun 2026 |
| Aberdeen Group PLC | 3.15M | 1.32% | +36.31% | Sep 2026 |
| Trails Edge Capital Partners, LP | 2.66M | 1.11% | 0.00% | Jun 2026 |
| Franklin Templeton Inc | 2.64M | 1.11% | +7.35% | Jun 2026 |
| Squadron Capital Management LLC | 2.44M | 1.02% | +355.14% | Jun 2026 |
| Woodline Partners LP | 2.32M | 0.97% | 0.00% | Jun 2026 |
| UBS Group AG | 2.31M | 0.96% | -0.58% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 2.00M | 0.84% | +36.27% | Jun 2026 |
| NEXTBio Capital Management LP | 1.79M | 0.75% | +34.08% | Jun 2026 |
| Citadel Advisors Llc | 1.78M | 0.75% | +2,647.60% | Jun 2026 |
| Ameriprise Financial Inc | 1.70M | 0.71% | +101.03% | Jun 2026 |
| Point72 Asset Management, L.P. | 1.68M | 0.70% | +76.01% | Jun 2026 |
| Integral Health Asset Management, LLC | 1.52M | 0.64% | +280.00% | Jun 2026 |
| Yu Fan | 1.50M | 0.63% | 0.00% | Jun 2026 |
Inventiva Sa company profile
- Company name
- Inventiva Sa
- Ticker
- IVA.US
- Exchange
- USA Stocks
- Listed since
- Jul 10, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 87
- Fiscal year end
- December
- Address
- 50 rue de Dijon, Daix, France, 21121
- Phone
- 33 3 80 44 75 00
- Website
- inventivapharma.com
About Inventiva Sa
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Inventiva Sa management
10- Mr. Andrew ObenshainChief Executive Officer · born 1974
- Dr. Pierre Broqua Ph.D.Co-Founder · born 1962
- Mr. Jean VolatierExecutive VP Finance & Corporate Social Responsibility · born 1965
- Dr. Martine Zimmermann Pharm.D.Executive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory Affairs · born 1969
- Mr. Jason A. Campagna M.D., Ph.D.President of Research & Development and Chief Medical Officer · born 1966
- Mr. Axel-Sven MalkomesChief Financial Officer · born 1967
- Mr. Christopher Benecchi M.B.A.Chief Operating Officer · born 1972
- Ms. Jennifer NavaChief Information Officer
- Ms. Susan ColesChief Legal Officer · born 1966
- Ms. Pamela HerbsterChief People Officer